supported by the Beijing Municipal Foundation for Clinical Research[Z181100001718033];the Project for Prevention and Treatment of AIDS and Viral Hepatitis[2018ZX10301-404];the National Major Science and Technology Project of China[2019YFC0840704].
Background and aims:Cessation of nucleoside/nucleotide analogue(Nuc)therapy in patients with HBeAg-negative chronic hepatitis B(CHB)remains controversial.Methods:In this prospective,single-center cohort study,we recru...
supported by National Key R&D Program of China(2023YFC2306800);National Natural Science Foundation of China(No.82072280 and No.82272315);Beijing Municipal Natural Science Foundation(No.7212063 and No.7222108).
Naturally occurred precore(PC,G1896A)and/or basal core promoter(BCP,A1762T/G1764A)mutations are prevalent in chronic HBV-infected patients,especially those under HBeAg-negative status.However,the replicative capacity ...